NCT02179515View on ClinicalTrials.gov

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 28, 2014

Primary Completion Date

April 6, 2017

Study Completion Date

February 28, 2018

Conditions
Lung CancerBreast CancerProstate CancerTumors (Others)Ovarian Cancer
Interventions
BIOLOGICAL

MVA-brachyury- TRICOM

It is an active cancer immunotherapy administered via subcutaneous injection.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02179515 - Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | Biotech Hunter | Biotech Hunter